Table 3.
Factors Associated with Obtaining an Additional Opiate Prescription Within 30 Days or More Than 60 Days After Ureteroscopy
| Within 30 days | After 60 days | |||
|---|---|---|---|---|
| Variable | OR (95% CI) | p-value | OR (95% CI) | p-value |
| Age | 0.97 (0.93–0.99) | 0.009 | 1.01 (0.98–1.06) | 0.32 |
| BMI | 1.01 (0.96–1.07) | 0.61 | 0.95 (0.87–1.03) | 0.23 |
| Female | 0.55 (0.23–1.35) | 0.19 | 0.68 (0.22–2.11) | 0.51 |
| Caucasian | 0.97 (0.21–4.54) | 0.97 | 1.99 (0.41–9.72) | 0.40 |
| ASA score | 0.88 (0.38–2.03) | 0.76 | 0.54 (1.18–24.82) | 0.03 |
| ASA 2 | 0.47 (0.085–2.57) | 0.38 | UTC | UTC |
| ASA 3 | 0.43 (0.080–2.30) | 0.32 | UTC | UTC |
| ASA 4 | 1.17 (0.074–18.35) | 0.91 | UTC | UTC |
| Prior psychiatric diagnosis | 2.07 (0.79–5.39) | 0.14 | 1.33 (0.35–5.03) | 0.67 |
| Prior stone procedure | 1.08 (0.46–2.53) | 0.87 | 0.62 (0.19–2.05) | 0.44 |
| Chronic opiate use | 2.61 (0.86–7.89) | 0.09 | UTC | UTC |
| Preoperative opiate prescriptions, number | 1.58 (1.6–2.37) | 0.026 | 1.57 (1.14–2.16) | 0.005 |
| Preoperative opiate prescription, days | 1.6 (1.11–2.32) | 0.012 | 1.02 (1.00–1.03) | 0.032 |
| Preoperative providers prescribing opiates | 1.68 (1.08–2.62) | 0.022 | 1.55 (1.00–2.39) | 0.048 |
| Preoperative MED prescribed | ||||
| Group 1 (lower tertile) | 0.39 (0.08–1.91) | 0.24 | 2.58 (0.42–16.0) | 0.31 |
| Group 2 (middle tertile) | 1.11 (0.31–3.93) | 0.88 | 4.79 (0.84–27.42) | 0.08 |
| Group 3 (upper tertile) | 3.35 (1.22–9.14) | 0.02 | 5.49 (1.02–29.63) | 0.048 |
| Preoperative oxybutynin prescription | 1.09 (0.41–2.92) | 0.86 | UTC | UTC |
| Preoperative tamsulosin prescription | 0.48 (0.16–1.47) | 0.20 | 0.19 (0.02–1.52) | 0.12 |
| Preoperative phenazopyridine | 0.89 (0.32–2.53) | 0.83 | 0.59 (0.13–2.72) | 0.49 |
| Postoperative opiate prescriptions, days | 1.0 (0.86–1.16) | 0.98 | 0.9 (0.70–1.15) | 0.38 |
| Postoperative MED prescribed | 1.0 (1.00–1.00) | 0.99 | 1.00 (0.99–1.01) | 0.79 |
| Postoperative oxybutynin | 1.38 (0.49–3.89) | 0.54 | 1.24 (0.33–4.62) | 0.75 |
| Postoperative tamsulosin | 1.5 (0.54–4.22) | 0.44 | 2.26 (0.49–10.4) | 0.30 |
| Postoperative phenazopyridine | 1.38 (0.49–3.89) | 0.54 | 4.64 (0.59–36.3) | 0.14 |
| Stone size, diameter | 0.96 (0.87–1.06) | 0.40 | 0.99 (0.88–1.11) | 0.83 |
| Operative time, minutes | 1.0 (0.99–1.02) | 0.81 | 1.00 (0.98–1.02) | 0.87 |
| Ureteral access sheath use | 0.84 (0.36–1.96) | 0.70 | 1.24 (0.40–3.83) | 0.71 |
| Laterality | ||||
| Left | 1.47 (0.39–5.55) | 0.57 | 1.45 (0.29–7.18) | 0.65 |
| Right | 1.67 (0.43–6.48) | 0.46 | 0.94 (0.16–5.41) | 0.95 |
| Preoperative ureteral stent | 0.76 (0.30–1.91) | 0.56 | 0.53 (0.14–1.96) | 0.34 |
| Postoperative ureteral stent duration, days | ||||
| 1–3 | 0.4 (0.06–2.70) | 0.35 | UTC | UTC |
| 4–7 | 0.38 (0.07–2.08) | 0.27 | UTC | UTC |
| 7+ | 0.43 (00.07–2.74) | 0.37 | UTC | UTC |
Due to small sample size of patients who required opiate prescriptions 60 days after ureteroscopy, several data points had frequency of zero and OR was unable to be calculated.
OR = odds ratio; UTC = unable to calculate.